Onconova Therapeutics, Inc. (ONTX) Coverage Initiated at HC Wainwright

Equities researchers at HC Wainwright assumed coverage on shares of Onconova Therapeutics, Inc. (NASDAQ:ONTX) in a research report issued to clients and investors on Monday. The brokerage set a “buy” rating and a $6.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 154.24% from the company’s current price.

ONTX has been the subject of several other reports. Maxim Group set a $6.00 price objective on Onconova Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, August 15th. ValuEngine upgraded Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Dawson James restated a “buy” rating on shares of Onconova Therapeutics in a research note on Tuesday, July 25th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. Onconova Therapeutics currently has a consensus rating of “Buy” and an average target price of $7.33.

Onconova Therapeutics (NASDAQ ONTX) opened at 2.36 on Monday. The firm’s 50-day moving average price is $1.71 and its 200 day moving average price is $2.05. The company’s market capitalization is $23.25 million. Onconova Therapeutics has a one year low of $1.46 and a one year high of $3.88.

Onconova Therapeutics (NASDAQ:ONTX) last posted its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.43. The firm had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.25 million. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 762.13%. On average, equities research analysts expect that Onconova Therapeutics will post ($2.92) earnings per share for the current fiscal year.

WARNING: This news story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/11/onconova-therapeutics-inc-ontx-coverage-initiated-at-hc-wainwright.html.

Several large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Onconova Therapeutics by 58.4% in the 2nd quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock valued at $190,000 after acquiring an additional 32,418 shares during the last quarter. Sabby Management LLC lifted its holdings in shares of Onconova Therapeutics by 104.0% in the 2nd quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock valued at $1,693,000 after acquiring an additional 399,640 shares during the last quarter. Finally, Tyndall Capital Partners L P lifted its holdings in shares of Onconova Therapeutics by 91.4% in the 2nd quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock valued at $2,154,000 after acqu

ONTX has been the subject of several other reports. Maxim Group set a $6.00 price objective on Onconova Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, August 15th. ValuEngine upgraded Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Dawson James restated a “buy” rating on shares of Onconova Therapeutics in a research note on Tuesday, July 25th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. Onconova Therapeutics currently has a consensus rating of “Buy” and an average target price of $7.33.

Onconova Therapeutics (NASDAQ ONTX) opened at 2.36 on Monday. The firm’s 50-day moving average price is $1.71 and its 200 day moving average price is $2.05. The company’s market capitalization is $23.25 million. Onconova Therapeutics has a one year low of $1.46 and a one year high of $3.88.

Onconova Therapeutics (NASDAQ:ONTX) last posted its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.43. The firm had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.25 million. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 762.13%. On average, equities research analysts expect that Onconova Therapeutics will post ($2.92) earnings per share for the current fiscal year.

WARNING: This news story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/11/onconova-therapeutics-inc-ontx-coverage-initiated-at-hc-wainwright.html.

Several large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Onconova Therapeutics by 58.4% in the 2nd quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock valued at $190,000 after acquiring an additional 32,418 shares during the last quarter. Sabby Management LLC lifted its holdings in shares of Onconova Therapeutics by 104.0% in the 2nd quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock valued at $1,693,000 after acquiring an additional 399,640 shares during the last quarter. Finally, Tyndall Capital Partners L P lifted its holdings in shares of Onconova Therapeutics by 91.4% in the 2nd quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock valued at $2,154,000 after acquiring an additional 476,190 shares during the last quarter. 26.83% of the stock is owned by hedge funds and other institutional investors.

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Receive News & Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply